Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Operations (2016 - 2025)

Abeona Therapeutics has reported Cash from Operations over the past 15 years, most recently at 17953000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 17953000.0 for Q4 2025, down 8.42% from a year ago — trailing twelve months through Dec 2025 was 76326000.0 (down 36.26% YoY), and the annual figure for FY2025 was 76326000.0, down 36.26%.
  • Cash from Operations for Q4 2025 was 17953000.0 at Abeona Therapeutics, up from 21187000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for ABEO hit a ceiling of 5746000.0 in Q3 2023 and a floor of 30257000.0 in Q4 2021.
  • Median Cash from Operations over the past 5 years was 13134500.0 (2021), compared with a mean of 13924900.0.
  • Biggest five-year swings in Cash from Operations: tumbled 1779.32% in 2021 and later surged 53.76% in 2022.
  • Abeona Therapeutics' Cash from Operations stood at 30257000.0 in 2021, then soared by 53.76% to 13992000.0 in 2022, then surged by 34.0% to 9235000.0 in 2023, then plummeted by 79.31% to 16559000.0 in 2024, then dropped by 8.42% to 17953000.0 in 2025.
  • The last three reported values for Cash from Operations were 17953000.0 (Q4 2025), 21187000.0 (Q3 2025), and 18784000.0 (Q2 2025) per Business Quant data.